Application of Tracer Methodology to the Study of Biogenic Amines

  • C. R. Creveling


The availability of isotopically labeled biogenic amines, such as norepinephrine, epinephrine, dopamine, serotonin, and histamine, has greatly increased the scope and ease of investigations of amine uptake, binding, release, biosynthesis, and metabolism. Such amines are now available with specific activities high enough (5 to 10 c/mmole) to permit studies with amine concentrations within the physiological range. This is particularly advantageous since studies now can be carried out undistorted by the gross pharmacological changes which accompany the use of larger amounts of nonisotopic biogenic amines.


Biogenic Amine Sympathetic Nerve Terminal Storage Granule Dansyl Derivative Cardiac Norepinephrine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Axelrod, J., Weil-Malherbe, H., and Tomchick, R., J. Pharmacol. 127: 251 (1959).Google Scholar
  2. 2.
    Whitby, L.G., Axelrod, J., and Weil-Malherbe, H., J. Pharmacol. 132: 193 (1961).Google Scholar
  3. 3.
    Shore, P.A., Pharmacol. Rev. 14: 531 (1963).Google Scholar
  4. 4.
    Zaimis, E., Ann. Rev. Pharmacol. 4: 365 (1964).CrossRefGoogle Scholar
  5. 5.
    Iversen, L.L., in Harper, N.J., and Simmonds, A.B. (editors), Advances in Drug Research, Vol. II, Academic Press, London and New York, 1965.Google Scholar
  6. 6.
    Glowinski, J., and Axelrod, J., Pharmacol. Rev. 18: 775 (1966).Google Scholar
  7. 7.
    Daly, J. W., Creveling, C.R., and Witkop, B., J. Med. Chem. 9: 273 (1966).CrossRefGoogle Scholar
  8. 8.
    Daly, J. W., Creveling, C.R., and Witkop, B., J. Med. Chem. 9: 280 (1966).CrossRefGoogle Scholar
  9. 9.
    Creveling, C.R., Daly, J.W., and Witkop, B., J. Med. Chem. 9: 284 (1966).CrossRefGoogle Scholar
  10. 10.
    Bacq, Z. M., and Renson, J., Bull. Acad. Roy. Med. Belg. 25: 755 (1966).Google Scholar
  11. 11.
    Daly, J.W., Axelrod, J., and Witkop, B., Ann. N.Y. Acad. Sci. 96: 37 (1962).CrossRefGoogle Scholar
  12. 12.
    Iversen, L.L., Brit. J. Pharmacol. 25: 18 (1965).Google Scholar
  13. 13.
    Burgen, A.S. V., and Iversen, L. L., Brit. J. Pharmacol. 25: 34 (1965).Google Scholar
  14. 14.
    Creveling, C.R., Daly, J.W., Witkop, B., and Udenfriend, S., Biochim. Biophys. Acta. 64: 125 (1962).CrossRefGoogle Scholar
  15. 15.
    Musacchio, J., Kopin, I. J., and Weise, V. K., J. Pharmacol. Exp. Therap. 148: 22 (1965).Google Scholar
  16. 16.
    Fischer, J.E., Horst, W.D., and Kopin, I.J., Brit. J. Pharmacol. 24: 477 (1965).Google Scholar
  17. 17.
    Cohen, R.A., Ann. Intern. Med. 65: 347 (1966).Google Scholar
  18. 18.
    Daly, J. W., Kondo, K., and Creveling, C.R., in preparation.Google Scholar
  19. 19.
    Trendelenberg, U., J. Pharmacol. 125: 55 (1959).Google Scholar
  20. 20.
    Hertting, G., Axelrod, J., and Patrick, R. W., Brit. J. Pharmacol. 18: 161 (1962).Google Scholar
  21. 21.
    Creveling, C.R., Daly, J. W., and Witkop, B., in preparation.Google Scholar
  22. 22.
    Porter, C.C., Totaro, J. A., and Stone, C.A., J. Pharmacol. Exp. Therap. 140: 308 (1963).Google Scholar
  23. 23.
    Spector, S., personal communication.Google Scholar
  24. 24.
    Lindmar, R., and Muschol, E., Arch. Exp. Pathol. Pharmakol. 247: 469 (1964).CrossRefGoogle Scholar

Copyright information

© New England Nuclear Corporation 1968

Authors and Affiliations

  • C. R. Creveling
    • 1
  1. 1.National Institutes of HealthNIAMDBethesdaUSA

Personalised recommendations